Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD) - Top-Institutions - MDSpire

Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD)

  • By

  • Ye Li

  • Xiangyu Fu

  • Ling Huang

  • Lirong Xiao

  • Danian Chen

  • April 24, 2026

  • 0 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Bascom Palmer Eye Institute, University of Miami
    Bascom Palmer Eye Institute, University of Miami

    Miami, FL

    Key Differentiators

    • Ophthalmology
    • Retina
    • Macular Degeneration

  • #2

    Massachusetts Eye and Ear Infirmary, Harvard Medical School
    Massachusetts Eye and Ear Infirmary, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Imaging

  • #3

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Research

  • #4

    Moorfields Eye Hospital and UCL Institute of Ophthalmology
    Moorfields Eye Hospital and UCL Institute of Ophthalmology

    London, N/A

    Key Differentiators

    • Ophthalmology
    • Retina
    • Imaging

  • #5

    University of California, San Francisco (UCSF) Department of Ophthalmology
    University of California, San Francisco (UCSF) Department of Ophthalmology

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Trials

Original Source(s)

Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD)

  • by Ye Li, Xiangyu Fu, Ling Huang, Lirong Xiao, Danian Chen

  • April 24, 2026

Related Content

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min
Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

Lutein Supplementation May Improve Outcomes in Early AMD

Meta-analysis found statistically significant improvements, with clearest benefits in early-stage disease